Minimal, synthetic arginine deiminase pathway provides full ATP demand for cellular growth
Bottom-up construction of synthetic cells requires a simple, yet robust ATP-generating system. The arginine deiminase (ADI) pathway offers a minimal, enzyme-based alternative to more complex ATP-producing systems such as glycolytic routes, respiratory chains or photosystems. Here, we implement the ADI pathway in Escherichia coli and test its capacity to fully replace native ATP generation. First, we designed and tested synthetic ADI operons through combinatorial library screening and selected high-performing variants. Using the best performing-ADI variant, we progressively reduced the cells dependence on native ATP generation while increasing selection for ADI-dependent growth through targeted knockout strains and growth conditions, followed by adaptive laboratory evolution. This resulted in a strain in which the ADI pathway sustained growth in minimal medium at a doubling time of 21 hours, serving as the sole source of ATP. Whole-genome sequencing of evolved strains revealed that this transition required loss-of-function mutations in the native respiratory chain. These findings demonstrate that the ATP supply of a cell can be fully supported by the ADI pathway, which has not been demonstrated in nature. Moreover, the ability of the pathway to sustain growth with a relatively high growth rate highlights its potential to fully power synthetic cells and support other biotechnological applications.